Expert consensus on clinical application of 177Lu-prostate specific membrane antigen radio-ligand therapy in prostate cancer
-
LIU Guobing,
-
ZHUO Weihai,
-
GU Yushen,
-
YANG Zhi,
-
CHEN Yue,
-
FAN Wei,
-
GUO Jianming,
-
TAN Jian,
-
ZHU Xiaohua,
-
HUO Li,
-
LAN Xiaoli,
-
LI Biao,
-
MIAO Weibing,
-
SONG Shaoli,
-
XU Hao,
-
TIAN Rong,
-
LUO Quanyong,
-
WANG Feng,
-
WANG Xuemei,
-
YANG Aimin,
-
DAI Dong,
-
DENG Zhiyong,
-
ZHAO Jinhua,
-
CHEN Xiaoliang,
-
FAN Yan,
-
GAO Zairong,
-
HAN Xingmin,
-
JIANG Ningyi,
-
KUANG Anren,
-
LIN Yansong,
-
LIU Fugeng,
-
LOU Cen,
-
SU Xinhui,
-
TANG Lijun,
-
WANG Hui,
-
WANG Xinlu,
-
YANG Fuzhou,
-
YANG Hui,
-
ZHAO Xinming,
-
YANG Bo,
-
HUANG Xiaodong,
-
CHEN Jiliang,
-
LI Sijin,
-
WANG Jing,
-
LI Yaming,
-
SHI Hongcheng
-
Graphical Abstract
-
Abstract
177Lu- prostate specific membrane antigen (PSMA) radio-ligand therapy has been approved abroad for advanced prostate cancer and has been in several clinical trials in China. Based on domestic clinical practice and experimental data and referred to international experience and viewpoints, the expert group forms a consensus on the clinical application of 177Lu-PSMA radio-ligand therapy in prostate cancer to guide clinical practice.
-
-
DownLoad: